Pain Medicine Department — Biomedical Watch V2

Traitements3programmes

Essais1liés

Publications5liées

SourceDBlocale

Traitements

3

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
Greater Occipital Nerve Block with 0.9% salineThe study was carried to determine the analgesic efficacy of greater occipital nerve block in patients of migraine. It was a randomised controlled which took place from april 2022 - october 2022. Fifty patients suffering from migraine were included in the study. Patients in Group G were given greater occipital nerve block (GONB) with lignocaine and dexamethasone under ultrasound guidance while those in Group S were given saline 0.9% as placebo. Pain score using Numeric Rating Scale and number of headache days was assessed at four,eight and twelve weeks after the procedure as a primary outcome. Total headache days were recorded as a secondary outcome.	Migraine	Phase 4	Traitement symptomatique	Pakistan	À vérifier
Greater Occipital Nerve Block with dexamethasone and lidocaineThe study was carried to determine the analgesic efficacy of greater occipital nerve block in patients of migraine. It was a randomised controlled which took place from april 2022 - october 2022. Fifty patients suffering from migraine were included in the study. Patients in Group G were given greater occipital nerve block (GONB) with lignocaine and dexamethasone under ultrasound guidance while those in Group S were given saline 0.9% as placebo. Pain score using Numeric Rating Scale and number of headache days was assessed at four,eight and twelve weeks after the procedure as a primary outcome. Total headache days were recorded as a secondary outcome.	Migraine	Phase 4	Traitement symptomatique	Pakistan	À vérifier
Greater Occipital Nerve Block with dexamethasone and lidocaineThe study was carried to determine the analgesic efficacy of greater occipital nerve block in patients of migraine. It was a randomised controlled which took place from april 2022 - october 2022. Fifty patients suffering from migraine were included in the study. Patients in Group G were given greater occipital nerve block (GONB) with lignocaine and dexamethasone under ultrasound guidance while those in Group S were given saline 0.9% as placebo. Pain score using Numeric Rating Scale and number of headache days was assessed at four,eight and twelve weeks after the procedure as a primary outcome. Total headache days were recorded as a secondary outcome.	Migraine	Phase 4	Traitement symptomatique	Pakistan	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
Greater Occipital Nerve Block with dexamethasone and lidocaine	Migraine	Phase 4	NCT05679765	Efficacy of GONB in Patients of Migraine	COMPLETED

Publications

5

Molécule	Indication / population	Titre	Journal	Date
Greater Occipital Nerve Block with 0.9% saline		Ultrasound-guided 5-in-1 trigger point injection for treating tension-type headache: A case report.	Medicine
Greater Occipital Nerve Block with 0.9% saline		Three men in a boat: The comparison of the combination therapy of botulinum toxin and greater occipital nerve block with bupivacaine, with botulinum toxin monotherapy in the management of chronic migraine.	Clinical neurology and neurosurgery
Greater Occipital Nerve Block with 0.9% saline		Greater occipital nerve blockade for the preventive treatment of chronic migraine: A randomized double-blind placebo-controlled study.	Cephalalgia : an international journal of headache
Greater Occipital Nerve Block with dexamethasone and lidocaine		Efficacy of Greater Occipital Nerve Blockade in Craniofacial Neuralgia and Facial Pain Syndromes: A Retrospective Chart Review with Prospectively Collected Follow-Up Data.	Journal of clinical medicine
Greater Occipital Nerve Block with dexamethasone and lidocaine		2025 guideline update to acute treatment of migraine for adults in the emergency department: The American Headache Society evidence assessment of parenteral pharmacotherapies.	Headache